Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Medical Devices

  • Print
  • Share
  • E-mail
-

Penumbra, Inc. Neuron 6F 070 Delivery Catheter (Original Version)

Recall Class: Class I
Date Recall
Initiated:		 September 22, 2009
Product: Penumbra Neuron 6F 070 Delivery Catheter (Original Version)
Catalog Numbers Lot Numbers
PND6F0701058, PND6F0701058M, PND6F070956,
PND6F070956M		 F13773, F13799, F13733, F13751, F13817, F13826, F13856, F13865, F13880, F13899, F13934, F13960, F13970, F13971, F13980, F13997, F14007, F14028, F14045, F14046, F14047, F14048, F14102, F14103, F14150, F14182, F14183, F14427, F14482, F14560, F14629
This product was distributed from November 2008 to May 2009.
Use: The Neuron 6F 070 Delivery Catheter is a component of the Neuron Intracranial Access System, which is used by physicians to introduce medical devices into blood vessels.
Recalling Firm: Penumbra, Inc.
1351 Harbor Bay Parkway
Alameda, California 94502-6541
Reason for Recall: The device may kink and/or break which may lead to longer surgery times, patient injury or death.
Public Contact:

Consumers may contact the company at 1-888-272-4606 or 1-510-748-3200, Monday - Friday, 8 AM to 5 PM Pacific Time.

For more information, see Useful Links below.
FDA District: San Francisco
FDA Comments:

On September 22, 2009, the company sent their customers a field removal letter requesting that they inspect their stock, remove all affected devices and return them to the company. The company will replace the affected devices. The company also asked their customers to complete and sign a product identification/return form.

Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious injury or death.

Health care professionals and consumers may report adverse reactions or quality problems experienced with the use of these products to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by FAX.

Useful Links:
-
-